Pre-Market Scans on Biotechnology Stocks -- Sunesis Pharma, Biogen, Array BioPharma, Seres Therapeutics, and Athersys

Aug 03, 2015, 09:20 ET from www.equityresearchinstitute.com

NEW YORK, August 3, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Biogen Inc. (NASDAQ: BIIB), Array BioPharma Inc. (NASDAQ: ARRY), Seres Therapeutics Inc. (NASDAQ: MCRB), and Athersys Inc. (NASDAQ: ATHX). Free research report on Sunesis Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=SNSS On Friday, July 31, 2015, the NASDAQ Composite ended at 5,128.28, down 0.01%, the Dow Jones Industrial Average edged 0.32% lower, to finish the day at 17,689.86, and the S&P 500 closed at 2,103.84, down 0.23%. The gains were broad based as five out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.  

Sunesis Pharmaceuticals Inc.'s stock lost 5.10%, to close the day at $1.39. The stock recorded a trading volume of 4.26 million shares, much above its three months average volume of 2.14 million shares. Over the last one month and over the past three months, Sunesis Pharmaceuticals Inc.'s shares have plummeted 57.08% and 38.27%, respectively. Furthermore, the stock has lost 45.29% since the start of this year. The company's shares are trading 41.38% below their 200-day moving average. Additionally, Sunesis Pharmaceuticals Inc. has a Relative Strength Index (RSI) of 30.81. Sign up and read the free notes on SNSS at:

https://www.EquityResearchInstitute.com/reports?keyword=SNSS

On Friday, shares in Biogen Inc. recorded a trading volume of 2.24 million shares, higher than their three months average volume of 1.91 million shares. The stock ended the day 0.56% higher at $318.78. Shares of the company traded at a PE ratio of 21.57. Biogen Inc.'s stock has lost 21.37% in the last one month, 17.46% in the previous three months and 6.09% on YTD basis. The stock is trading below its 50-day and 200-day moving averages by 18.18% and 15.13%, respectively. Furthermore, shares of Biogen Inc. have an RSI of 29.82. The complimentary notes on BIIB can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=BIIB

Array BioPharma Inc.'s stock gained 1.04%, to close Friday's session at $5.81. The stock recorded a trading volume of 1.00 million shares, below its three months average volume of 1.81 million shares. Over the last one month and the previous three months, Array BioPharma Inc.'s shares have declined 17.24% and 8.07%, respectively. However, the stock has surged 22.83% since the start of this year. The company's shares are trading 18.87% and 7.87% below their 50-day and 200-day moving averages, respectively. Furthermore, Array BioPharma Inc.'s stock has an RSI of 24.38. Register for free on Equity Research Institute and access the latest research on ARRY at:

https://www.EquityResearchInstitute.com/reports?keyword=ARRY

Seres Therapeutics Inc.'s stock finished Friday's session 0.47% lower at $37.85. A total of 0.16 million shares were traded, which was below its three months average volume of 0.63 million shares. Over the last one month and since the beginning of 2015, Seres Therapeutics Inc.'s shares have lost 4.90% and 26.36%, respectively. The company's shares are trading below their 50-day and 200-day moving averages by 7.23%, each. The complete research on MCRB is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=MCRB

On Friday, shares in Athersys Inc. ended the session 1.87% lower at $1.05. The stock reported a trading volume of 0.60 million shares, close to its three months average volume of 0.58 million shares. Athersys Inc.'s shares have declined 13.22% in the last one month, 9.48% in the previous three months and 33.54% on YTD basis. The stock is trading 14.30% below its 50-day moving average and 39.32% below its 200-day moving average. Moreover, shares of Athersys Inc. have an RSI of 30.84. Free in-depth research on ATHX is available at:

https://www.EquityResearchInstitute.com/reports?keyword=ATHX

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com